Matthew E. Korenberg

CIK: 0001649903

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (18.2%)

Position reduction

Option Exercises (M)8 (36.4%)

Derivative conversions

Awards (A)6 (27.3%)

Compensation grants

Other (G, F, J, C, D, …)4 (18.2%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

PVLA

PALVELLA THERAPEUTICS, INC.

Officer

$LIFECORE BIOMEDICAL, INC. \DE\ logo$

LFCR

LIFECORE BIOMEDICAL, INC. \DE\

Director

LGND

LIGAND PHARMACEUTICALS INC

Officer

Discretionary Trading P&L

Holdings

Transaction History (22 total)

PVLA
PALVELLA THERAPEUTICS, INC.
Jun 12, 2026
Exercise(M)
Direct
1K shares at avg. $13.60$14K
$LIFECORE BIOMEDICAL, INC. \DE\ logo$
LFCR
LIFECORE BIOMEDICAL, INC. \DE\
Jun 4, 2026
Award(A)
Direct
25.9K shares-
PVLA
PALVELLA THERAPEUTICS, INC.
Feb 5, 2026
Award(A)
Stock Option (Right to Buy)
Direct
44.1K shares-
$LIFECORE BIOMEDICAL, INC. \DE\ logo$
LFCR
LIFECORE BIOMEDICAL, INC. \DE\
Jul 15, 2025
Award(A)
Direct
19.5K shares-
PVLA
PALVELLA THERAPEUTICS, INC.
Feb 5, 2025
Award(A)
Incentive Stock Option (right to buy)
Direct
5.4K shares-
PVLA
PALVELLA THERAPEUTICS, INC.
Feb 5, 2025
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
123.6K shares-
PVLA
PALVELLA THERAPEUTICS, INC.
Dec 13, 2024
Award(A)
Stock Option (right to buy)
Direct
167.1K shares-
LGND
LIGAND PHARMACEUTICALS INC
Sep 23, 2024
Exercise(M)
Direct
9.4K shares at avg. $52.84$495K
LGND
LIGAND PHARMACEUTICALS INC
Sep 23, 2024
Sale(S)
Direct
7.1K shares at avg. $101.61$720K
LGND
LIGAND PHARMACEUTICALS INC
Sep 23, 2024
Sale(S)
Direct
201 shares at avg. $102.05$21K
LGND
LIGAND PHARMACEUTICALS INC
Sep 23, 2024
Sale(S)
Direct
2.5K shares at avg. $100.05$248K
LGND
LIGAND PHARMACEUTICALS INC
Sep 23, 2024
Exercise(M)
Direct
395 shares at avg. $49.99$20K
LGND
LIGAND PHARMACEUTICALS INC
Sep 20, 2024
Exercise(M)
Direct
5K shares at avg. $49.99$249K
LGND
LIGAND PHARMACEUTICALS INC
Sep 20, 2024
Sale(S)
Direct
6.3K shares at avg. $104.10$653K
LGND
LIGAND PHARMACEUTICALS INC
Sep 16, 2024
Exercise(M)
Direct
671 shares at avg. $49.99$34K
LGND
LIGAND PHARMACEUTICALS INC
Sep 16, 2024
Tax Payment(F)
Direct
319 shares at avg. $105.00$33K
LGND
LIGAND PHARMACEUTICALS INC
Sep 16, 2024
Exercise(M)
Direct
3.3K shares at avg. $60.94$204K
LGND
LIGAND PHARMACEUTICALS INC
Sep 16, 2024
Tax Payment(F)
Direct
1.9K shares at avg. $105.00$203K
LGND
LIGAND PHARMACEUTICALS INC
Sep 16, 2024
Exercise(M)
Direct
849 shares at avg. $58.49$50K
LGND
LIGAND PHARMACEUTICALS INC
Sep 16, 2024
Tax Payment(F)
Direct
485 shares at avg. $105.00$51K
LGND
LIGAND PHARMACEUTICALS INC
Sep 16, 2024
Exercise(M)
Direct
914 shares at avg. $55.75$51K
LGND
LIGAND PHARMACEUTICALS INC
Sep 16, 2024
Tax Payment(F)
Direct
472 shares at avg. $105.00$50K

		Type	Shares	Price		Ownership
Jun 12, 2026	PVLA PALVELLA THERAPEUTICS, INC.	Exercise(M)	1,000	$13.60	$13,600	Direct
Jun 4, 2026	$LIFECORE BIOMEDICAL, INC. \DE\ logo$ LFCR LIFECORE BIOMEDICAL, INC. \DE\	Award(A)	25,907	-	$0	Direct
Feb 5, 2026	PVLA PALVELLA THERAPEUTICS, INC.	Award(A) Stock Option (Right to Buy)	44,123	-	-	Direct
Jul 15, 2025	$LIFECORE BIOMEDICAL, INC. \DE\ logo$ LFCR LIFECORE BIOMEDICAL, INC. \DE\	Award(A)	19,506	-	-	Direct
Feb 5, 2025	PVLA PALVELLA THERAPEUTICS, INC.	Award(A) Incentive Stock Option (right to buy)	5,373	-	-	Direct
Feb 5, 2025	PVLA PALVELLA THERAPEUTICS, INC.	Award(A) Non-Qualified Stock Option (right to buy)	123,559	-	-	Direct
Dec 13, 2024	PVLA PALVELLA THERAPEUTICS, INC.	Award(A) Stock Option (right to buy)	167,100	-	-	Direct
Sep 23, 2024	LGND LIGAND PHARMACEUTICALS INC	Exercise(M)	9,377	$52.84	$495,481	Direct
Sep 23, 2024	LGND LIGAND PHARMACEUTICALS INC	Sale(S)	7,090	$101.61	$720,379	Direct
Sep 23, 2024	LGND LIGAND PHARMACEUTICALS INC	Sale(S)	201	$102.05	$20,513	Direct
Sep 23, 2024	LGND LIGAND PHARMACEUTICALS INC	Sale(S)	2,481	$100.05	$248,228	Direct
Sep 23, 2024	LGND LIGAND PHARMACEUTICALS INC	Exercise(M)	395	$49.99	$19,746	Direct
Sep 20, 2024	LGND LIGAND PHARMACEUTICALS INC	Exercise(M)	4,982	$49.99	$249,050	Direct
Sep 20, 2024	LGND LIGAND PHARMACEUTICALS INC	Sale(S)	6,275	$104.10	$653,238	Direct
Sep 16, 2024	LGND LIGAND PHARMACEUTICALS INC	Exercise(M)	671	$49.99	$33,543	Direct
Sep 16, 2024	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	319	$105.00	$33,495	Direct
Sep 16, 2024	LGND LIGAND PHARMACEUTICALS INC	Exercise(M)	3,340	$60.94	$203,540	Direct
Sep 16, 2024	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	1,938	$105.00	$203,490	Direct
Sep 16, 2024	LGND LIGAND PHARMACEUTICALS INC	Exercise(M)	849	$58.49	$49,658	Direct
Sep 16, 2024	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	485	$105.00	$50,925	Direct
Sep 16, 2024	LGND LIGAND PHARMACEUTICALS INC	Exercise(M)	914	$55.75	$50,956	Direct
Sep 16, 2024	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	472	$105.00	$49,560	Direct

1-22 of 22 transactions

About Korenberg Matthew E

Korenberg Matthew E (SEC CIK 0001649903) files insider reports with the SEC as CFO, Treasurer of PALVELLA THERAPEUTICS, INC. (PVLA), Director of LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) and President & COO of LIGAND PHARMACEUTICALS INC (LGND).

Signal8 holds 9 ownership filings by Korenberg Matthew E (1 Form 3, 8 Form 4), filed between Sep 18, 2024 and Jun 16, 2026. Those filings report 22 transactions, from Sep 16, 2024 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Korenberg Matthew E's filings is in CHASKA, MN.

Recent filings by Korenberg Matthew E

Jun 12, 2026: Option exercise of PVLA shares (Form 4, code M).
Jun 4, 2026: Grant or award of LFCR shares (Form 4, code A).
Feb 5, 2026: Grant or award of PVLA derivative securities (Form 4, code A).
Jul 15, 2025: Grant or award of LFCR shares (Form 4, code A).
Feb 5, 2025: Grants or awards of PVLA derivative securities (2 lines, Form 4, code A).

Other insiders filing for PALVELLA THERAPEUTICS, INC. (PVLA)

Goin Kathleen, Chief Operating Officer
JENKINS GEORGE M, Director
KIRITSY CHRISTOPHER P, Director
Pauls Matthew, Director
HERON ELAINE J, Director
Doux John, Director

How to read Form 4 transaction codes